{"nctId":"NCT00668707","briefTitle":"Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality","startDateStruct":{"date":"2007-09"},"conditions":["Non Small Cell Lung Cancer"],"count":709,"armGroups":[{"label":"Melatonin","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: melatonin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: placebo"]}],"interventions":[{"name":"melatonin","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of non small cell lung cancer\n* Eligible for surgical resection\n* Willingness to adhere to randomized treatment\n* Availability for follow-up schedule of visits\n\nExclusion Criteria:\n\n* Taking exogenous melatonin","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Lung Cancer Recurrence or Mortality - 2 Years","description":"Disease-Free survival (DFS) at 2 years post-surgery. DFS is measured by the number of participants in both arms who have experienced a recurrence OR mortality at 2 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life","description":"Participant-reported quality of life using the European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire C-30 (EORTC QLQ C-30) and Lung Cancer 13 (EORTC QLQ LC13) questionnaires. Scores represent a value from 0-100. Symptom and LC13 scale: 0 represents best health, 100 worst health. Global and functional scales: 100 represents best health, 0 represents worst health. Full scoring algorithms available here: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":null},{"groupId":"OG001","value":"20.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"15.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":null},{"groupId":"OG001","value":"75.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.9","spread":null},{"groupId":"OG001","value":"81.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.2","spread":null},{"groupId":"OG001","value":"80.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":null},{"groupId":"OG001","value":"62.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":null},{"groupId":"OG001","value":"71.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":null},{"groupId":"OG001","value":"72.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"19.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"18.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null},{"groupId":"OG001","value":"17.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Fatigue","description":"Measured using the Multidimensional Fatigue Inventory 20 (MFI-20) questionnaire. Scores are on a scale of 0-100, where 100 is the best health and 0 is the worst health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","spread":null},{"groupId":"OG001","value":"57.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":null},{"groupId":"OG001","value":"62.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","spread":null},{"groupId":"OG001","value":"63.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Sleep","description":"Measured using the Medical Outcomes Study (MOS) Sleep Survey. Scales used were Sleep Adequacy and Sleep problems Index II. Scores are on a scale of 0-100. Sleep Adequacy: 100 represents best health; 0 represents worst health. Problems index: 0 represents best health; 100 represents worst health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7","spread":null},{"groupId":"OG001","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null},{"groupId":"OG001","value":"61.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"60.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":null},{"groupId":"OG001","value":"33.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"27.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.5","spread":null},{"groupId":"OG001","value":"26.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Levels","description":"Calculated using the Brief Pain Inventory. Each scale ranges from 0-10, where 0 is no pain and 10 is the worst possible pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"2.4"},{"groupId":"OG001","value":"2.3","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"2.1"},{"groupId":"OG001","value":"2.4","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Anxiety","description":"Measured using the Beck Anxiety Inventory. Scored range from 0-63, where 0 is no anxiety and 63 is the worst possible anxiety.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"8.5"},{"groupId":"OG001","value":"8.3","spread":"8.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"6.9"},{"groupId":"OG001","value":"6.4","spread":"7.6"}]}]}]},{"type":"SECONDARY","title":"Depression","description":"Measured using the Beck Depression Inventory II. Scores range from 0-63, where 0 is no depression and 63 is the worst possible depression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"7.2"},{"groupId":"OG001","value":"8.6","spread":"8.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"5.9"},{"groupId":"OG001","value":"7.7","spread":"8.0"}]}]}]},{"type":"SECONDARY","title":"Adverse Events (Chemotherapy)","description":"Number of participants who experienced an adverse event related to their adjuvant chemotherapy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Lung Cancer Recurrence or Mortality - 5 Years","description":"Measured as disease-free survival (DFS) at 5 years. DFS was measured by the incidence of a recurrence OR mortality up to 5 years post-surgery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Blood Tests to Examine the Effects of Melatonin on the Immune System (Raw Values)","description":"NK cell cytotoxicity changes from baseline to 6 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.8","spread":"3.6"},{"groupId":"OG001","value":"42.7","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.2","spread":"3.0"},{"groupId":"OG001","value":"46.4","spread":"3.8"}]}]}]},{"type":"SECONDARY","title":"Adverse Events (Radiation)","description":"Number of participants who experienced an adverse event related to their adjuvant radiation therapy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Blood Tests to Examine the Effects of Melatonin on the Immune System (Comparison Between Groups)","description":"Differences in NK cell cytotoxicity between both arms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"1.16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":84,"n":356},"commonTop":["Fatgiue","Insomnia","Nausea","Dyspnea","Diarrhea"]}}}